Davide Bonanni

Davide Bonanni

Auto-generated profile, based on publicly available information

Davide Bonanni

Department of Drug Science and Technology, University of Turin, via P. Giuria 9, Turin 10125, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSStefano Sainas
Stefano Sainas
APAgnese Chiara Pippione
Agnese Chiara Pippione
ELElisa Lupino
Elisa Lupino
MGMarta Giorgis
Marta Giorgis
PCPaola Circosta
Paola Circosta
MLMarco L. Lolli
Marco L. Lolli

28 January 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MLMarco L. Lolli
Marco L. Lolli
ICIrene M. Carnovale
Irene M. Carnovale
APAgnese Chiara Pippione
Agnese Chiara Pippione
WWWeixiao Y. Wahlgren
Weixiao Y. Wahlgren
DBDavide Bonanni
Davide Bonanni
DBDonatella Boschi
Donatella Boschi

12 April 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SSStefano Sainas
Stefano Sainas
MGMarta Giorgis
Marta Giorgis
PCPaola Circosta
Paola Circosta
VGValentina Gaidano
Valentina Gaidano
DBDavide Bonanni
Davide Bonanni
MLMarco L. Lolli
Marco L. Lolli
The connection with acute myelogenous leukemia (AML) of dihydroorotate dehydrogenase (hDHODH), a key enzyme in pyrimidine biosynthesis, has attracted significant interest from pharma as a possible AML therapeutic target. We recently discovered compound 1, a potent hDHODH inhibitor (IC50 = 1.2 nM), able to induce myeloid differentiation in AML cell lines (THP1) in the low nM range (EC50 = 32.8 nM) superior to brequinar’s phase I/II clinical trial (EC50 = 265 nM). Herein, we investigate the 1 drug-like properties observing good metabolic stability and no toxic profile when administered at doses of 10 and 25 mg/kg every 3 days for 5 weeks (Balb/c mice). Moreover, in order to identify a backup compound, we investigate the SAR of this class of compounds. Inside the series, 17 is characterized by higher potency in inducing myeloid differentiation (EC50 = 17.3 nM), strong proapoptotic properties (EC50 = 20.2 nM), and low cytotoxicity toward non-AML cells (EC30(Jurkat) > 100 μM).

26 September 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SSStefano Sainas
Stefano Sainas
MGMarta Giorgis
Marta Giorgis
PCPaola Circosta
Paola Circosta
GPGiulio Poli
Giulio Poli
MAMarta Alberti
Marta Alberti
MLMarco L. Lolli
Marco L. Lolli
In recent years, human dihydroorotate dehydrogenase inhibitors have been associated with acute myelogenous leukemia as well as studied as potent host targeting antivirals. Starting from MEDS433 (IC50 1.2 nM), we kept improving the structure-activity relationship of this class of compounds characterized by 2-hydroxypyrazolo[1,5-a]pyridine scaffold. Using an in silico/crystallography supported design, we identified compound 4 (IC50 7.2 nM), characterized by the presence of a decorated aryloxyaryl moiety that replaced the biphenyl scaffold, with potent inhibition and pro-differentiating abilities on AML THP1 cells (EC50 74 nM), superior to those of brequinar (EC50 249 nM) and boosted when in combination with dipyridamole. Finally, compound 4 has an extremely low cytotoxicity on non-AML cells as well as MEDS433; it has shown a significant antileukemic activity in vivo in a xenograft mouse model of AML.

15 January 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DBDavide Bonanni
Davide Bonanni
MLMarco L. Lolli
Marco L. Lolli
Jürgen BajorathJürgen Bajorath
Jürgen Bajorath

27 June 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
ASAna R. N. Santos
Ana R. N. Santos
HSHelen Sheldrake
Helen Sheldrake
AIAli I. M. Ibrahim
Ali I. M. Ibrahim
CDChhanda Charan Danta
Chhanda Charan Danta
DBDavide Bonanni
Davide Bonanni
KPKlaus Pors
Klaus Pors
Tetrahydroisoquinoline (THIQ) is a key structural component in many biologically active molecules including natural products and synthetic pharmaceuticals.